Abstract:ObjectiveThe objective of this study was to evaluate total protein (TP) in the cerebrospinal fluid (CSF) and immunoglobulins in the serum and CSF in patients with sporadic amyotrophic lateral sclerosis (sALS). We also assessed the correlations of these variables with sALS progression and severity and estimated their roles in predicting prognosis.MethodsWe retrospectively collected data on CSF TP and immunoglobulins in the CSF and serum, including immunoglobulin G, immunoglobulin A and immunoglobulin M, from 326 sALS patients. The relationships between these variables and clinical features, including sex, age, disease duration, site of onset, respiratory function and survival time, were analysed by Wilcoxon's nonparametric tests. Kaplan–Meier and Cox proportional hazards models were used to explore whether levels of TP and immunoglobulins in the CSF were independently correlated with the survival time of patients with ALS.ResultsThe CSF TP was elevated in 55% of the patients. The median CSF TP was 417.7 (349.4–539.5) mg/L, and 6 patients (2%) had a CSF TP level greater than 1000 mg/L. The CSF TP levels were significantly higher in male patients than in female patients {501.5 (195.6) versus 419.5 (170.3) mg/L, p < .001}. In females, the CSF TP had positive associations with onset age (rho =0.196, p = .021) and disease progression rate (DPR) (rho =0.230, p = .035) but negative associations with disease duration (rho = −0.204, p = .016) and revised ALS functional rating scale (ALSFRS-R) (rho = −0.288, p = .008). The ALSFRS-R scores of male patients were negatively correlated with the s-IgM levels (rho = −0.562, p = .005). Onset age was negatively associated with the s-IgM levels (rho = −0.534, p = .005) in females. Kaplan–Meier survival analyses showed that no correlations were found between survival time and the levels of TP and immunoglobulins in the CSF.ConclusionElevated levels of TP and immunoglobulins in the CSF suggest impaired blood-brain barrier (BBB) function and immune responses in the CNS of ALS patients. Higher CSF TP levels were associated with later onset age, a shorter disease duration and worse disease severity in females. The changes in the levels of CSF TP and s-IgM might indicate the severity of the disease in some ALS patients.

Association of serum Spp1 levels with disease progression in ALS and SBMA

Inflammatory signature in amyotrophic lateral sclerosis predicting disease progression

SerpinA1 levels in amyotrophic lateral sclerosis patients: An exploratory study

The increase in CSF total protein and immunoglobulins in Chinese patients with sporadic amyotrophic lateral sclerosis: A retrospective study

A New Molecular Perspective

Serum Cytokines Profile Changes in Amyotrophic Lateral Sclerosis

Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy

The Spatiotemporal Expression of SOCS3 in the Brainstem and Spinal Cord of Amyotrophic Lateral Sclerosis Mice

Serum SOD1 level predicts the severity and prognosis of community-acquired pneumonia patients

Sarm1 knockout modifies biomarkers of neurodegeneration and spinal cord circuitry but not disease progression in the mSOD1G93A mouse model of ALS

Prognostic Value of Systemic Inflammation, Nutritional Status and Sarcopenia in Patients With Amyotrophic Lateral Sclerosis

Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders

Abnormal Brain Protein Abundance and Cross-tissue mRNA Expression in Amyotrophic Lateral Sclerosis

Associations of cerebrospinal fluid profiles with severity and mortality risk of amyotrophic lateral sclerosis

Increased Interleukin-6 Levels in the Astrocyte-Derived Exosomes of Sporadic Amyotrophic Lateral Sclerosis Patients

The role of peripheral immunity in ALS: a population-based study

Peripheral immunity relate to disease progression and prognosis in amyotrophic lateral sclerosis

Biomarkers in cerebrospinal fluid for amyotrophic lateral sclerosis phenotypes

Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy

Serum heat shock protein concentrations are not associated with amyotrophic lateral sclerosis risk or survival in three European populations